About axim biotechnologies inc - AXIM
AXIM Biotechnologies, Inc. operates as a biotechnology company, which engages in the development of diagnostic healthcare solutions. Its product categories include Eye Health, SARS-CoV-2, and fentanyl neutralizing antibody test. The company was founded on November 18, 2010 and is headquartered in San Diego, CA.
AXIM At a Glance
AXIM Biotechnologies, Inc.
6191 Cornerstone Court East
San Diego, California 92121
| Phone | 1-858-923-4422 | Revenue | 70.46K | |
| Industry | Pharmaceuticals: Other | Net Income | -3,512,466.00 | |
| Sector | Health Technology | 2024 Sales Growth | 78.293% | |
| Fiscal Year-end | 12 / 2025 | Employees | 7 | |
| View SEC Filings |
AXIM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 8.599 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -5.445 |
| Enterprise Value to Sales | 102.845 |
| Total Debt to Enterprise Value | 0.916 |
AXIM Efficiency
| Revenue/Employee | 10,065.429 |
| Income Per Employee | -501,780.857 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.019 |
AXIM Liquidity
| Current Ratio | 0.00 |
| Quick Ratio | 0.00 |
| Cash Ratio | 0.00 |
AXIM Profitability
| Gross Margin | -524.104 |
| Operating Margin | -2,502.313 |
| Pretax Margin | -4,985.191 |
| Net Margin | -4,985.191 |
| Return on Assets | -92.515 |
| Return on Equity | N/A |
| Return on Total Capital | 92.946 |
| Return on Invested Capital | N/A |
AXIM Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -175.721 |
| Total Debt to Total Assets | 192.63 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -173.671 |